Navigation Links
BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Date:8/13/2008

ological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. The potential benefit of the drug for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide (MBP8298), if approved, has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

About Multiple Sclerosis

------------------------

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 years of age. MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, which interferes with messages from the brain to the body. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis. Approximately 40 percent of all MS patients have the secondary progressive form of the disease.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical Announces Second Quarter 2008 Results
2. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
3. BioMS Medical to present at BMO Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medical to present at Jefferies Healthcare Conference
6. BioMS Medical to present at 2008 BIO International Convention
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical announces first quarter 2008 results
9. BioMs Medical to present at TIDES(R) Conference
10. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
11. BioMS Medical Provides Update On Pipeline Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... London (PRWEB) May 28, 2015 ... Computer Aided Engineering software, announced today it is ... (PSRI). CD-adapco will provide state-of-the-art engineering simulation tools ... share their expertise and experiences in analyzing particle ... industry members and advance the understanding of flow ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Glenn Keet, ... The Changing Landscape of EMR/EHR Clinical Data Integration with ... taking place in Washington, DC on June 14th-18th. , ... of integrating EMR/EHR systems with EDC, and will examine ... brought by eSource and electronic health records/electronic medical records ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Global ... a point to ask his audiences if they ... trends including robotics, solar cells, fuel cells, rapid ... printers, advanced battery storage technology, driverless cars, artificial ... high-quality but inexpensive online education. , While ...
(Date:5/28/2015)... Virginia (PRWEB) May 28, 2015 ... LLC announced today that Roger L. Williams, MD, ... consultant. NDA Partners Premier Experts are top tier ... to bring extraordinary value to the company’s clients. ... solutions to help clients successfully develop their medical ...
Breaking Biology Technology:CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2
... (NYSE: DGX ), the nation,s leading provider of ... to speak,at the 2007 UBS Global Life Sciences Conference ... Quest Diagnostics presentation is scheduled to,begin at 4:30 p.m. ... during the conference and will be,available to registered investors ...
... California coast to ... by arthritis, SAN FRANCISCO, Sept. 21 More than ... Classic,Bike Tour on Saturday, September 29 in San Francisco. Participants, ... to raise more,than $1.3 million this year for the Arthritis ...
... Private equity investor The Blackstone Group now represented on company,s ... ... 21 Stiefel Laboratories, Inc.,today announced the appointment of two new members ... private,equity firm The Blackstone Group, which recently became a minority-share,investor in the ...
Cached Biology Technology:Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference 2More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation 2Stiefel Laboratories Appoints Two New Members to Board of Directors 2Stiefel Laboratories Appoints Two New Members to Board of Directors 3
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... Cold Spring Harbor, N.Y. As the body ages, ... appear, physical exertion becomes harder. But there are also ... is another phenomenon at work, which may contribute to ... ] published in the journal Nature Neuroscience ...
... identified seven new gene loci linked to obesity. Researchers were also ... are similar to those that cause milder forms of overweight and ... in the study of the links between genes and obesity, which ... . The aim of the study was to identify new genes ...
... identified four genes newly associated with severe childhood obesity. ... variations in severely obese children. The team found ... help to maintain protein receptors known to be involved ... targets for the development of new drugs against obesity. ...
Cached Biology News:CSHL neuroscientists show 'jumping genes' may contribute to aging-related brain defects 2CSHL neuroscientists show 'jumping genes' may contribute to aging-related brain defects 3Genes behind obesity mapped in large-scale study 2Finding genes for childhood obesity 2
... The user-friendly Eppendorf Thermomixer R ... preparations that require shaking, heating, and ... greatly expanded its application and temperature ... can each accommodate 24 micro test ...
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 19 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
... sufficient materials for 1,464 array sample elements. , , ... , Blocker BSA in PBS (10X): 50 ml , ... Saline: 8 packs , 10% Tween-20: 2 x 10 ... x 25 ml , SuperSignal West Pico Stable Peroxide: ...
Biology Products: